Selank: What Neuroactive Peptide Research Shows
Selank is a synthetic peptide examined in neuroactive and immune-signalling research, and this article reviews findings and limitations of the evidence.
By UAE Peptide Clinic Research Desk
Selank is a synthetic heptapeptide developed in Russia as a derivative of the endogenous tetrapeptide tuftsin. It has been studied for more than two decades, primarily for anxiolytic (anti-anxiety) effects. Unusually for such a compound, published studies have not reported sedation or cognitive impairment, which has made it of research interest where mental clarity and stress resilience matter.
Mechanism of Action
Selank acts through multiple neurological pathways. It appears to modulate the GABAergic system, the primary inhibitory neurotransmitter system, without acting directly as a GABA receptor agonist. This distinguishes it from benzodiazepines and is thought to explain why dependence, sedation and withdrawal effects have not been reported in published studies. It also influences brain-derived neurotrophic factor (BDNF) expression, serotonin turnover, and the enkephalin system.
Clinical Applications
Selank has been studied in relation to anxiety, stress resilience and cognitive performance under pressure. In Russia, it is registered for anxiety and asthenic conditions.
- Studied format: intranasal
- Studied for GABAergic modulation; sedation and dependence not reported in published trials
- Also examined for effects on BDNF, serotonin, and enkephalin pathways
- Registered in Russia for anxiety and asthenic conditions
Whether any protocol is appropriate is a decision for an independent DHA-licensed physician. Read more on the Selank page.
If you want to understand whether any of this is relevant to you, an independent DHA-licensed physician can review your case. Take the two-minute quiz at /find-my-stack or book a physician consultation at /book (AED 300 deposit, credited to your first order).
